Catalent has received a project grant as part of a consortium looking to develop and manufacture thermo stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Currently, 90% of existing vaccines are cold-chain dependent, and the goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent.                                                                   A total project fund of €5.3 million has be...